Department of Neurology Odense University Hospital Odense C Denmark.
Brain Behav. 2017 May 8;7(6):e00696. doi: 10.1002/brb3.696. eCollection 2017 Jun.
The introduction of interferon beta therapies more than 20 years ago marked a milestone in the treatment of relapsing-remitting multiple sclerosis (RRMS) with a significant impact on the approach to modern multiple sclerosis (MS) care. Key learnings and perspectives from the early days of disease modifying therapies in MS have improved the knowledge base of MS, need for treatment, and patient care. The continuous development of interferons over the past two decades outlines a journey with increased understanding of the pharmacodynamics and pharmacokinetic mechanisms of interferons, leading to innovative formulations with an improved benefit/risk profile.
20 多年前，干扰素 β 疗法的问世标志着复发缓解型多发性硬化症（RRMS）治疗的一个里程碑，对现代多发性硬化症（MS）治疗方法产生了重大影响。MS 疾病修正治疗早期的关键经验和观点提高了 MS 的知识基础、治疗需求和患者护理水平。过去 20 年来，干扰素的不断发展勾勒出了一幅不断深入了解干扰素的药效学和药代动力学机制的历程，从而产生了具有改善的获益/风险特征的创新配方。
